ARTELO BIOSCIENCES INC

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

ARTL$2.14+3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at December 31, 2024 and 2023

Consolidated Balance Sheets

(In thousands, except share data)

	December 31,	December 31,
	2024	2023
ASSETS
Current Assets
Cash and cash equivalents	$2,338	$2,815
Trading marketable securities	-	7,611
Prepaid expenses and other current assets	219	554
Total Current Assets	2,557	10,980
Operating lease right-of-use assets	99	21
Intangible asset	2,039	2,039
Other assets	3	3
TOTAL ASSETS	$4,698	$13,043
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities	$1,679	$1,238
Due to related parties	61	30
Operating lease liabilities - current portion	35	23
Total Current Liabilities	1,772	1,291
Operating lease liabilities	69	-
TOTAL LIABILITIES	1,841	1,291
STOCKHOLDERS' EQUITY
Preferred Stock, par value $0.001, 416,667 shares authorized,
0 shares issued and outstanding as of December 31, 2024, and 2023	-	-
Common Stock, par value $0.001, 50,000,000 shares authorized and
3,281,032 and 3,188,959 shares issued and outstanding as of December 31, 2024, and 2023, respectively	3	3
Additional paid-in capital	53,192	52,262
Accumulated deficit	(50,136)	(40,310)
Accumulated other comprehensive loss	(202)	(203)
TOTAL STOCKHOLDERS' EQUITY	2,857	11,752
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$4,698	$13,043

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.